Nazol Kids Nasal Spray, 0.25%, 10 mL per bottle with a spray nozzle.
Ingredients
Active ingredient: phenylephrine hydrochloride;
1 mL of the product contains 2.5 mg of phenylephrine hydrochloride (0.25%);
excipients: eucalyptol, glycerin, benzalkonium chloride, macrogol 1500, sodium hydrophosphate dihydrate, potassium dihydrogenphosphate, disodium edetate dihydrate, purified water.
Dosage Form
Nasal spray.
Main physical and chemical properties: a clear, colorless or pale yellow liquid with an eucalyptus odor.
Pharmacotherapeutic group
Decongestants and other nasal preparations for topical use. Sympathomimetics, simple preparations. ATC code R01A A04.
Pharmacological properties
Pharmacodynamics.
Phenylephrine hydrochloride is a synthetic adrenomimetic. By stimulating the α-adrenoreceptors of blood vessels, it produces a pronounced vasoconstrictive effect. The vasoconstrictive effect manifests as a reduction in blood flow and swelling of the mucous membranes of the nose, paranasal sinuses, and Eustachian tube. This restores nasal breathing, which had been impaired by the flu, colds, and allergic conditions.
Pharmacokinetics.
Local vasoconstriction of the nasal mucosa and paranasal sinuses occurs 3–5 minutes after administration of the drug into the nasal cavity. The anti-edema effect lasts up to 6 hours.
Indications
Acute rhinitis caused by the common cold, the flu, or allergic conditions; sinusitis. Acute otitis media (as an adjunctive treatment).
Contraindications
Hypersensitivity to any component of the drug (allergic reactions), severe forms of hypertension, tachysystolic arrhythmias, acute cardiovascular diseases, decompensated heart failure, cardiac conduction disturbances, renal failure, thyrotoxicosis, acute pancreatitis, hepatitis, inflammation of the skin and mucous membranes of the anterior nasal cavity and a tendency to develop nasal crusts (atrophic rhinitis), conditions following transsphenoidal hypophysectomy; concomitant use with monoamine oxidase inhibitors and for 15 days after discontinuation of treatment with MAO inhibitors.
Drug Interactions and Other Interactions
Should not be used concomitantly with other vasoconstrictors (regardless of the route of administration) or with antihypertensive medications (β-blockers).
Atropine sulfate blocks the reflex bradycardia caused by phenylephrine and increases the vasopressor response to phenylephrine. Concomitant use of phenylephrine with beta-blockers may lead to hypertension and excessive bradycardia with possible heart block. Use with caution when administered with thyroid hormones or medications that affect cardiac conduction (cardiac glycosides, antiarrhythmic drugs). When used concomitantly with drugs that cause potassium loss, such as certain furosemide-type diuretics, hypokalemia may be exacerbated and arterial sensitivity to vasopressor drugs such as phenylephrine may be reduced.
Concomitant use of phenylephrine and other sympathomimetics may lead to additional stimulation of the central nervous system to an extremely high level, accompanied by nervousness, irritability, and insomnia. Seizures are also possible. In addition, concomitant use of other sympathomimetics with phenylephrine may lead to an increase in the vasoconstrictive or cardiovascular effects of either of these two medications.
Concomitant use with MAO inhibitors is contraindicated. Treatment with this drug should be initiated at least 15 days after discontinuation of MAO inhibitor therapy, as pressor effects may be potentiated (see the “Contraindications” section).
Concomitant use of phenylephrine with linezolid is not recommended.
Special Instructions for Use
To prevent the spread of infection, individual use of the spray is recommended.
Persistent nasal congestion after 3 days of use may indicate a deviated nasal septum, purulent sinusitis, adenoid hypertrophy, allergic rhinitis, a persistent bacterial infection, or other conditions requiring consultation with a specialist and specialized comprehensive treatment.
This medication should be used with caution in patients with hypertension, cardiovascular diseases, thyroid disorders (except those listed in the “Contraindications” section), angle-closure glaucoma, or diabetes mellitus. In these cases, consult a doctor before starting treatment.
This medication should be used under adult supervision.
If children under 12 years of age experience nervousness, dizziness, or insomnia, stop using the medication and consult a doctor.
Use During Pregnancy or Breastfeeding.
This medication is not intended for use during pregnancy or while breastfeeding.
Effect on reaction time when driving or operating machinery.
This medication is not expected to affect reaction time when driving or operating machinery.
Dosage and Administration
Children aged 2 to 6 years: 1–2 doses of spray in each nostril no more frequently than every 6 hours. Children aged 6–12 years: 2–3 doses of spray in each nostril no more frequently than every 4 hours. Hold the bottle upright.
The duration of treatment usually does not exceed 3 days.
Children. Use in children aged 2 to 12 years under adult supervision.
Overdose
Although systemic side effects do not usually occur with topical use, an overdose may lead to an increase in the severity of side effects, especially with prolonged use. The following may occur: cardiac arrhythmias, increased blood pressure, hypotension, pain and discomfort in the chest area, palpitations, shortness of breath, non-cardiogenic pulmonary edema, agitation, convulsions, headache, tremor, sleep disturbances, restlessness, anxiety, nervousness, irritability, inappropriate behavior, psychosis with hallucinations, insomnia, weakness, anorexia, nausea, vomiting, oliguria, urinary retention, painful or difficult urination, facial flushing, cold sensation in the extremities, paresthesia, pale skin, piloerection, increased sweating, hyperglycemia, hypokalemia, constriction of peripheral and visceral blood vessels, reduced blood flow to vital organs, which may lead to impaired renal blood flow, metabolic acidosis, and increased cardiac workload due to increased total peripheral vascular resistance. Severe consequences of vasoconstriction are more likely in patients with hypovolemia and severe bradycardia. There is no specific antidote for phenylephrine poisoning. Treatment is symptomatic.
Side Effects
In rare cases, the following side effects may occur.
At the application site: irritation at the application site, sneezing, a burning sensation, and tingling in the nose.
Cardiovascular system: flushing, arrhythmia, bradycardia, increased blood pressure.
Nervous system: dizziness, anxiety, headache.
Immune system: allergic reactions, including cross-reactions in patients allergic to other sympathomimetics, which may manifest as rashes, itching, hives, angioedema (of the hands, face, or throat), a feeling of heaviness behind the breastbone, and difficulty breathing.
If the drug is used in doses higher than recommended, the symptoms listed in the “Overdose” section may occur.
Shelf life
2 years. Once the vial is opened, the shelf life is 12 months.
Storage Conditions
Store in the original packaging at a temperature not exceeding 25 °C. Keep out of the reach of children.
Packaging
A 10-ml plastic bottle with a spray nozzle in a cardboard box.
Dispensing Category
Available without a prescription.
Similar products
Products from the same category











